TOKYO - Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Maruho Co., Ltd. (hereafter, Maruho) issued a press release today, regarding the launch of Mitchga Subcutaneous Injection 30mg Vials (Japanese Accepted Name (JAN): nemolizumab (Genetical Recombination)) in Japan for the treatment of the following diseases only when existing treatment is insufficiently effective: pruritus associated with atopic dermatitis and prurigo nodularis.

Mitchga was originated from Chugai, and has been licensed-out to Maruho in Japan.

Please refer to the link below for details of the press release: Maruho Launches 'Mitchga Subcutaneous Injection 30mg Vials', an Antibody Treatment for Pruritus Associated with Atopic Dermatitis (Pediatric) and Prurigo Nodularis in Japan

Conatct:

Tel: +81-(0)3-3273-0554

Fax: +81-(0)3-3281-6607

(C) 2024 Electronic News Publishing, source ENP Newswire